Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
46 hedge funds and large institutions have $219M invested in Adaptimmune Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 8 closing their positions.
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
2% less funds holding
Funds holding: 47 → 46 (-1)
16% less capital invested
Capital invested by funds: $260M → $219M (-$40.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$3.75M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$3.02M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.06M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.53M |
| 5 |
Renaissance Technologies
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$8.6M |
| 2 |
Jennison Associates
New York
|
-$3.28M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$1.26M |
| 5 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$918K |
ADAP Hedge Fund Activity: Q3 2016 in Review
46 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2016, worth a combined $219M — down 16% from $260M a quarter earlier.
Fund positioning in ADAP was balanced in Q3 2016: 8 funds opened new positions, 8 closed out, 11 added to existing stakes and 11 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $3.75M. The largest seller was Foresite Capital Management II, exiting entirely with an estimated $8.6M sold.
- 46 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2016, down from 47 in Q2 2016.
- Funds reported $219M of Adaptimmune Therapeutics stock for Q3 2016, down 16% quarter-over-quarter.
- 8 funds opened new Adaptimmune Therapeutics positions in Q3 2016 and 8 closed out, a net change of 0 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2016 was Baillie Gifford & Co, an estimated $3.75M added.
- The largest Adaptimmune Therapeutics seller in Q3 2016 was Foresite Capital Management II, an estimated $8.6M sold.
Based on aggregated 13F filings for Q3 2016.